Inclusion Criteria

- INCLUSION CRITERIA RECIPIENT

5.1.1 Ages 10-75 years inclusive

5.1.2 Any one of the following hematologic conditions meeting a standard indication for
allogeneic stem cell transplant:

5.1.2.1 Chronic myelogenous leukemia (CML): Subjects under the age of 21 in chronic phase
OR Subjects ages 10-75 in chronic phase who have failed treatment with imatinib or have
intolerance to imatinib OR Subjects ages 10-75 in accelerated phase or blast
transformation. OR

5.1.2.2 Acute lymphoblastic leukemia (ALL): any of these categories: Adult ALL including
standard risk; Pediatric ALL in first remission with high-risk features (presenting
leukocyte count > 100,000/cu mm, karyotypes t(9; 22), t4, t19, t11, biphenotypic
leukemia). All second or subsequent remissions, primary induction failure, partially
responding or untreated relapse. OR

5.1.2.3 Acute myelogenous leukemia (AML): AML in first remission - except AML with good
risk karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), c-kit unmutated AML t (8; 21). All
AML in second or subsequent remission, primary induction failure and resistant relapse. OR

5.1.2.4 Myelodysplastic syndromes(MDS): any of these categories - refractory anemia with
transfusion dependence, refractory anemia with ANC< 500/microL, refractory anemia with
excess of blasts, transformation to acute leukemia, chronic myelomonocytic leukemia,
atypical MDS/myeloproliferative syndromes. OR

5.1.2.5 Myeloproliferative disorders including atypical (Ph-negative) chronic myeloid and
neutrophilic leukemias, progressing myelofibrosis, and polycythemia vera, essential
thrombocythemia either in transformation to acute leukemia or with progressive transfusion
requirements or pancytopenia. OR

5.1.2.6 Chronic lymphocytic leukemia refractory to fludarabine treatment and with bulky
progressive disease or with thrombocytopenia (less than or equal to 100,000 / microl) or
anemia (less than or equal to 10g/dl) not due to recent chemotherapy. OR

5.1.2.7 Non-Hodgkin's lymphoma including Mantle cell lymphoma relapsing or refractory to
standard of care treatments. OR

5.1.2.8 Multiple myeloma, Waldenstroms macroglobulinemia, unresponsive or relapsed
following standard of care treatments. OR

5.1.2.9 Hodgkin's Lymphoma relapsing following an autologous transplant.

5.1.3 HLA identical (6/6) related donor.

5.1.4 For adults: ability to comprehend the investigational nature of the study and
provide informed consent. For minors: written informed consent from one parent or
guardian. Informed oral assent from minors: the process will be explained to the minor on
a level of complexity appropriate for their age and ability to comprehend.

EXCLUSION CRITERIA RECIPIENT

5.2.1 Major anticipated illness or organ failure incompatible with survival from
transplant

5.2.2 Severe psychiatric illness or mental deficiency sufficiently severe as to make
compliance with the transplant treatment unlikely and making informed consent impossible.

5.2.3 Positive pregnancy test for women of childbearing age

5.2.4 DLCO adjusted for Hb and ventilation< 50% predicted

5.2.5 Left ventricular ejection fraction < 40% (evaluated by ECHO) or < 30% (evaluated
by MUGA)

5.2.6 AST/SGOT > 10 times ULN

5.2.7 Total bilirubin > 5 times ULN

5.2.8 Estimated GFR < 15 mL/min

5.2.9 Prior allogeneic stem cell transplantation

INCLUSION CRITERIA DONOR

5.3.1 Related donor, HLA identical (6/6) with recipient

5.3.2 Weight greater than or equal to 18 kg

5.3.3 Age greater than or equal to 2 or less than or equal to 80 years old

5.3.4 For adults: ability to comprehend the investigational nature of the study and
provide informed consent. For minors: written informed consent from one parent or guardian
and informed assent: The process will be explained to the minor on a level of complexity
appropriate for their age and ability to comprehend.

EXCLUSION CRITERIA DONOR

5.4.1 Pregnant or breast-feeding. Lactating donors are permitted provided breast milk is
discarded during the days filgrastim (G-CSF) is given

5.4.2 Unfit to receive G-CSF and undergo apheresis (abnormal blood counts, history of
stroke, uncontrolled hypertension)

5.4.3 Sickling hemoglobinopathy including HbSS, HbSC

5.4.4 Donors who are positive for HIV, active hepatitis B (HBV), hepatitis C (HCV) or
human Tcell lymphotropic virus (HTLV-I/II)

5.4.5 Severe psychiatric illness or mental deficiency sufficiently severe as to make
compliance with the donation process unlikely, and making informed consent impossible.